別品名 |
Sonolisib, (1E,4S,4aR,5R,6aS,9aR)-5-(acetyloxy)-1-[(di-2-propen-1-ylamino)methylene]-4,4a,5,6,?6a,8,9,9a-octahydro-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyclopenta[5,6]naphtho[1,2-c]pyran-2,7,10(1H)-trione
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
525.59
|
CAS RN® |
502632-66-8
|
化合物の概要 |
Wortmannin analog; PI3K inhibitor.
|
構造 |
C29H35NO8
|
溶媒 |
Methanol , DMSO(50mM), Ethyl acetate, Ethanol
|
使用目的 |
PX-866 is a wortmannin analog that inhibits PI3K, exhibiting anticancer chemotherapeutic and anti-angiogenic activities. PX-866 is currently in clinical trials as a standalone or combination therapy in the treatment of advanced solid tumors. PX-866 inhibits invasion and angiogenesis and induces autophagy in glioblastoma cells. In animal models of cancer, PX-866 inhibits tumor growth and increases survival time. PX-866 also inhibits motility of cancer cells.
|
その他 |
[融点]102oC-107oC
|
参考文献 |
Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 3;109(5):1085-92. PMID: 23942080.Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010 Jun;12(6):559-69. PMID: 20156803.Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther. 2007 Sep;6(9):2505-14. PMID: 17766839.
|
|
メーカー |
品番 |
包装 |
LKT
|
P9200
|
5 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
-20℃
|
|